First evaluation of the anxiolytic-like effects of a bromazepam‑palladium complex in mice.

A significant fraction of patients are affected by persistent fear and anxiety. Currently, there are several anxiolytic drug options, however their clinical outcomes do not fully manage the symptoms. Here, we evaluated the effects of a bromazepam‑palladium derivative [2-{(7-bromo-2-oxo-1,3-dihydro-2H-1,4-benzodiazepin-5-il)pyridinyl-κ-N,N}chloropalladium(II)], [(BMZ)PdCl], on fear/anxiety and memory-related behavior in mice.